Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
eNq9mF1v2jAUhu/5FVEudpeEFGhhC1QbazekVmO0aNNuKpMcipmxM3/w0V8/h9CVTo66GjwJCYjNe058jh+/JDlfL4i3BC4wo10/Duu+BzRlGab3XX98exm0/fNeLZmjJXqadqLnhXHseylBQnT9YjScAKIi/H599RH074H7vZqXsMkcUvlsnpKYhJ+RmF2jvJjjJUuGM28Bcsayrp8rub3qJUJynUVvxfhPkaMUkmh3ZX90ftfcv55Ehdg/qCoB/ArRe6MoUCvNVHEOVPaRhHvGNxX5Nqy0sRiBYIqnMERyNuRsiTPIjCGmiAiwCjJdZTfAlwRkEcQoHs3ThbASR3O0HsGvgTnp93q0L9cyqAfxWbsTN87O9Ou0bhWK7y2VuQr6JqL8rtHs1ButZgQ0IhuaI/6AAkaQ/oAnAVvqN0SDFNEUuGXRhoxLRByVC4v+845zFIfDrxfbIsMiJ2gTzkVuu1SIIz0MXHPB3Y0Ud3DLNamIXrO/9KkiJHpl1uMdRxxlXGCqzxSVFTi5HNkuRJ9RCevqitoRUK53vYhBHE/2gVEz/YdqQnBqyzpNIwVCjkeDatT9F0p8QALG3B0mvmGasZU4Pn72y+0o+3xLUKNozrP47qTTPo1bLevd9UP3VsWZdKE4yyHSYMLiEN4M6JQdShrdrmapx2Z136dby8RSRKDCNAWWNNIN+ujxnG0Bd9urHDCKfrq4te2brwr45mb71SiNs+6fituh2gX/dZe+lHi5n4vk6612p9F8gxb5u0c33rV03qWoE+OtuBk+Mylz8TaKVqtVOEMiEEivZzjlFqfGuXFNjrEuGtFPZXb3p8GJlyi9VYlnR6lPynP3dfW13dEvuY1DHfTu9zunbowhuYIDalHC3xmiBxfHp/6TfXaW9vAZe9yF2VpdJDGjrpyWmpiJfdA5o+tKL7kGxJfpFFc8xKnsyyQqHyD1aklUPDzq1X4DxGMncA==
9NWsUm9QckAhWcKV